Identifying Men Diagnosed with Clinically Localized Prostate Cancer Who Are at High Risk for Death from Prostate Cancer.
From: Department of Radiation Oncology, Brigham and Women’s Hospital and Dana Farber Cancer Institute, 75 Francis Street, Boston, MA 02215, USA. adamico@lroc.harvard.edu
The Journal of urology
- Publish Date: Dec 2006
- ISSN: 0022-5347
- Volume: 176
- Issue: 6 Pt 2
- Pages: S11-5
- Medium: Print
- Language: English
- Citation (JAMA): D'Amico Anthony V, Hui-Chen Ming, Renshaw Andrew A, et al. Identifying Men Diagnosed with Clinically Localized Prostate Cancer Who Are at High Risk for Death from Prostate Cancer.. J. Urol. Dec 2006;176:S11-5
Abstract
PURPOSE: We identified factors at diagnosis that are significantly associated with time to prostate cancer specific mortality following radical prostatectomy or external beam radiation therapy. MATERIALS AND METHODS: The study cohort included 1,453 men treated with radical prostatectomy (1,095) or external beam radiation therapy (358) for localized prostate cancer between 1989 and 2002. Cox regression multivariate analysis was used to evaluate whether prostate specific antigen, prostate specific antigen velocity, biopsy Gleason score and clinical tumor category at diagnosis were significantly associated with time to prostate cancer specific mortality following radical prostatectomy or external beam radiation therapy. RESULTS: In addition to increasing prostate specific antigen (p < or =0.04) and biopsy Gleason score 8 to 10 disease (p < or =0.02), prostate specific antigen velocity more than 2 ng/ml yearly was significantly associated with shorter time to prostate cancer specific mortality in patients treated with radical prostatectomy (adjusted HR 12, 95% CI 3 to 54) and external beam radiation therapy (adjusted HR 12, 95% CI 3 to 54) compared with that in men with prostate specific antigen velocity 2 ng/ml yearly or less (p < or =0.001). Despite low risk disease 7-year estimates of prostate cancer specific mortality were 5% to 19% in patients in whom prostate specific antigen increased by more than 2 ng/ml during the year before diagnosis compared with less than 1% in those with a prostate specific antigen increase of 2 ng/ml or less. CONCLUSIONS: Despite prostate specific antigen level less than 10 ng/ml and Gleason score 6 cancer a prostate specific antigen increase of more than 2 ng/ml during the year before diagnosis places a man at high risk for prostate cancer death following radical prostatectomy or external beam radiation therapy.
Mesh Headings (Keywords): Aged, Aged, 80 and over, Biopsy, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Patient Selection, Prognosis, Prostate-Specific Antigen, Prostatectomy, Prostatic Neoplasms, Radiotherapy, Adjuvant, Retrospective Studies, Risk Factors, Survival Rate
Check for Full Text / PubMed Unique Identifier (PMID): 17084157
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.